G1 Therapeutics, Inc. (GTHX), is a commercial-stage biopharmaceutical company specializing in the discovery, development, and delivery of modern therapies, introduced two scientific posters at the International Society for Pharmacoeconomics and Outcomes Research focusing on the approximate economic repercussions of treating myelosuppression along with patients with high-stage small cell lung cancer.
At last check-in after-market trading, shares of G1 Therapeutics Inc. (GTHX) declined -4.24% at $20.55. GTHX stock closed last session at $21.46, decreasing -2.05% or -$0.45. Shares of the company fluctuated between $20.56 and $22.00 throughout the day. The shares of G1 Therapeutics Inc. have advanced 8.71% in the last five days; however, they have lost -8.72% over the last month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
Measures For Treatment Of Myelosuppression
COSELA got approval by the FDA on February 12, 2021. The drug has been deemed suitable in reducing the incidence of chemotherapy-induced myelosuppression in adult patients affected with cancer when delivered before a platinum/etoposide-containing regimen or topotecan-containing regimen for high-stage small cell lung cancer.
The first poster depicts a cost-effective model forecasting the economic value from a U.S. commercial buyer’s perspective of using COSELA before chemotherapy in patients with high-stage small cell lung cancer. In accordance with the model, the anticipated total cost savings per patient could potentially be $15,006, an amount that is based on a forecast depletion in myelosuppressive unfavorable events (AEs) and their linked treatment expense.
The authors suggest that the model depicts that COSELA could potentially be an economically feasible innovation to facilitate ease and reduction in the incidence of myelosuppression in patients with ES-SCLC being administered with a platinum/etoposide-containing chemotherapy regimen.
The second poster establishes the impact of treatment-induced myelosuppression along Medicare patients affected with SCLC, hence providing the growing body of scientific evidence, depicting the essential health burden, financial toll, and quality of life effects of chemotherapy-induced myelosuppression.
Approximately 75% of patients treated with chemotherapy had been through anemia during the timeline studied. Neutropenia was diagnosed in 45.2% of chemotherapy-treated patients generally. Thrombocytopenia was reported in 27.0% of patients treated with chemotherapy overall. Pancytopenia was also seen in 24.4% of patients overall. During the same time frame, 74.3% of chemotherapy-treated patients had been through a minimum of one inpatient admission linked with myelosuppression.
Conclusion
Several adverse reactions to COSELA such as fatigue, hypocalcaemia, hypokalaemia and hypophosphatemia combined with acute drug hypersensitivity reactions and embryo-fetal toxicity has reduced investor interest, with GTHX stock price plummeting at last check.
